

20-10-2014

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra – East,
Mumbai

Sub: Unaudited Financial Results for the Quarter and half year ended 30th September, 2014

With reference to the captioned matter, this is to inform the Exchange that the Board of Directors of the Company at its meeting held today has, *inter alia*, approved Unaudited Financial Results for the quarter and half year ended on 30th September, 2014.

In this regard, we enclose herewith the following for the quarter and half year ended on 30th September, 2014:

1. Consolidated Unaudited Financial Results.
2. Statement of Consolidated Assets and Liabilities.
3. Standalone Unaudited Financial Results.
4. Statement of Standalone Assets and Liabilities.
5. Limited Review Report by Statutory Auditors on Standalone as well as on Consolidated Quarterly Financial Results.
6. Press Release dated 20th October, 2014.

Please take note of the same.

Thanking you,
For **Alembic Pharmaceuticals Limited**

A. K. Desai

Ajay Kumar Desai
Vice President-Finance
& Company Secretary

Encl.: A/a

CIN:
L24230GJ2010PLC061123

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280830 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

20-10-2014

To,
The Manager,
Department of Corporate Services,
Bombay Stock Exchange Limited
P. J. Towers, Dalal Street,
Fort, Mumbai

Sub: Unaudited Financial Results for the Quarter and half year ended 30th September, 2014

Dear Sir,

With reference to the captioned matter, this is to inform the Exchange that the Board of Directors of the Company at its meeting held today has, *inter alia*, approved Unaudited Financial Results for the quarter and half year ended on 30th September, 2014.

In this regard, we enclose herewith the following for the quarter and half year ended on 30th September, 2014:

1. Consolidated Unaudited Financial Results.
2. Statement of Consolidated Assets and Liabilities.
3. Standalone Unaudited Financial Results.
4. Statement of Standalone Assets and Liabilities.
5. Limited Review Report by Statutory Auditors on Standalone as well as on Consolidated Quarterly Financial Results.
6. Press Release dated 20th October, 2014.

Please take note of the same.

Thanking you,
For **Alembic Pharmaceuticals Limited**



Ajay Kumar Desai
Vice President-Finance
& Company Secretary

Encl.: A/a

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN:
L24230GJ2010PLC061123

**UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED 30TH SEPTEMBER, 2014**

Rs. in Lacs

	Particulars	CONSOLIDATED					
		Quarter Ended			Period Ended		Year Ended
		September-14	June-14	September-13	September-14	September-13	March-14
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
PART- I							
1 (a) Net Sales / Income from Operations							
Domestic		32,743	27,840	28,260	60,583	52,380	104,106
Exports		22,132	21,773	20,507	43,905	39,265	82,735
Total		54,875	49,613	48,767	104,488	91,645	186,841
Less : Excise Duty		250	248	177	498	395	771
Net Sales / Income from Operations		54,625	49,365	48,590	103,990	91,250	186,070
(b) Other Operating Income		83	63	46	146	103	251
Total Income from Operations		54,708	49,428	48,636	104,136	91,353	186,321
2 Expenses							
(a) Decrease/(Increase) in stock in trade and work in progress		(3,660)	(2,677)	(744)	(6,337)	(2,048)	(4,065)
(b) Consumption of Raw Materials & Packing Materials		15,501	14,728	13,764	30,229	27,361	55,593
(c) Purchase of traded goods		7,126	5,646	5,930	12,772	10,880	19,807
(d) Employees' Cost		7,677	7,561	5,931	15,238	11,567	24,700
(e) Marketing Expense		7,010	5,196	4,805	12,206	9,183	16,618
(f) Research and Development Expense		3,109	2,953	3,382	6,062	5,622	11,643
(g) Excise Duty		122	152	208	274	287	425
(h) Other Expenditure		6,997	6,202	6,088	13,199	12,082	25,829
Total Expenses		43,882	39,761	39,365	83,643	74,934	150,550
3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items		10,826	9,667	9,271	20,493	16,419	35,771
4 Other Income		14	18	20	32	22	319
5 Profit from Ordinary Activities before Interest, Depreciation, & Exceptional Items		10,840	9,685	9,291	20,525	16,441	36,090
6 Depreciation		1,084	1,071	985	2,155	1,938	4,049
7 Interest (Net)		104	56	257	160	404	981
8 CSR Expense		83	65	-	148	-	-
9 Net Profit from Ordinary Activities before Tax		9,569	8,493	8,049	18,062	14,099	31,060
10 Tax Expense							
Less : Provision for Current Tax		2,136	1,735	1,739	3,871	3,068	6,847
Less/(Add) : Provision for Deferred Tax Liability /(Assets)		(293)	293	146	-	203	663
11 Net Profit from Ordinary Activities after Tax		7,726	6,465	6,164	14,191	10,828	23,550
12 Share of Profit of Associates		1	2	-	3	-	-
13 Net Profit after Tax and share of profit of associates		7,727	6,467	6,164	14,194	10,828	23,550
14 Paid up Equity Share Capital (Face value of share ₹ 2/-)		3,770	3,770	3,770	3,770	3,770	3,770
15 Reserves excluding Revaluation Reserve		-	-	-	-	-	63,787
16 Basic & Diluted EPS (Not Annualised)		4.10	3.43	3.27	7.53	5.74	12.49
PART- II							
A Particulars of Shareholding							
1 Public Shareholding							
- Number of Shares		48777294	48777294	48777294	48777294	48777294	48777294
- Percentage of Shareholding		25.87	25.87	25.87	25.87	25.87	25.87
2 Promoters and Promoter Group Shareholding							
- Fully Non - Encumbered							
- Number of Shares		139738620	139738620	139738620	139738620	139738620	139738620
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)		100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)		74.13	74.13	74.13	74.13	74.13	74.13
B INVESTOR COMPLAINTS		Quarter Ended on 30th September, 2014					
Pending at the beginning of the quarter		NIL					
Received during the quarter		5					
Disposed of during the quarter		5					
Remaining unresolved at the end of the quarter		NIL					




Alembic Pharmaceuticals Limited

Consolidated Statement of Assets and Liabilities

Rs. In Lacs

Particulars		As at 30th September, 2014 (Unaudited)	As at 31st March, 2014 (Audited)
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital		3,770	3,770
(b) Reserves and surplus		77,629	63,787
Sub-total - Shareholders' funds		81,399	67,557
2 Non-current liabilities			
(a) Long-term borrowings		3,092	5,222
(b) Deferred tax liabilities (net)		2,272	2,272
(c) Other long-term liabilities		1,284	1,270
(d) Long-term provisions		832	668
Sub-total - Non-current liabilities		7,479	9,432
3 Current liabilities			
(a) Short-term borrowings		17,265	2,542
(b) Trade payables		37,181	28,844
(c) Other current liabilities		6,126	6,062
(d) Short-term provisions		1,754	7,343
Sub-total - Current liabilities		62,326	44,791
TOTAL - EQUITY AND LIABILITIES		151,204	121,780
B ASSETS			
1 Non-current assets			
(a) Fixed assets		46,341	41,763
(b) Non-current investments		334	336
(c) Long-term loans and advances		4,795	4,164
Sub-total - Non-current assets		51,471	46,263
2 Current assets			
(a) Inventories		38,428	31,078
(b) Trade receivables		36,800	27,337
(c) Cash and Bank Balance		5,256	2,396
(d) Short-term loans and advances		19,249	14,706
Sub-total - Current assets		99,734	75,517
TOTAL - ASSETS		151,204	121,780



**UNAUDITED FINANCIAL RESULTS
 FOR THE PERIOD ENDED 30TH SEPTEMBER, 2014**

Rs. In lacs

	Particulars	STANDALONE					
		Quarter Ended			Period Ended		Year Ended
		September-14	June-14	September-13	September-14	September-13	March-14
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
PART- I							
1	(a) Net Sales / Income from Operations						
	Domestic	32,743	27,840	28,260	60,583	52,380	104,106
	Exports	21,562	20,525	20,397	42,087	39,122	80,793
	Total	54,305	48,365	48,657	102,670	91,502	184,899
	Less : Excise Duty	250	248	177	498	395	771
	Net Sales / Income from Operations	54,055	48,117	48,480	102,172	91,107	184,128
	(b) Other Operating Income	83	63	46	146	103	251
	Total Income from Operations	54,138	48,180	48,526	102,318	91,210	184,379
2	Expenses						
	(a) Decrease/(Increase) in stock in trade and work in progress	(3,660)	(2,677)	(744)	(6,337)	(2,048)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	15,501	14,728	13,764	30,229	27,361	55,593
	(c) Purchase of traded goods	7,127	5,646	5,930	12,773	10,880	19,807
	(d) Employees' Cost	7,432	7,322	5,931	14,754	11,567	24,446
	(e) Marketing Expense	6,459	4,954	4,805	11,413	9,183	16,075
	(f) Research and Development Expense	2,770	2,754	3,121	5,524	5,190	10,510
	(g) Excise Duty	122	152	208	274	287	425
	(h) Other Expenditure	6,895	5,972	6,021	12,867	11,871	25,686
	Total Expenses	42,646	38,851	39,036	81,497	74,291	148,477
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	11,492	9,329	9,490	20,821	16,919	35,902
4	Other Income	14	18	20	32	22	319
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	11,506	9,347	9,510	20,853	16,941	36,221
6	Depreciation	1,084	1,071	985	2,155	1,938	4,049
7	Interest (Net)	92	56	257	148	404	981
8	CSR Expense	83	65	-	148	-	-
9	Net Profit from Ordinary Activities before Tax	10,247	8,155	8,268	18,402	14,599	31,191
10	Tax Expense						
	Less : Provision for Current Tax	2,135	1,714	1,739	3,849	3,066	6,700
	Less /Add : Provision for Deferred Tax Liability/(Assets)	(293)	293	146	-	203	663
11	Net Profit from Ordinary Activities after Tax	8,405	6,148	6,383	14,553	11,330	23,828
12	Paid up Equity Share Capital (Face value of share Rs. 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
13	Reserves excluding Revaluation Reserve	-	-	-	-	-	59,199
14	Basic & Diluted EPS (Not Annualised)	4.46	3.26	3.39	7.72	6.01	12.64
PART- II							
A	Particulars of Shareholding						
1	Public Shareholding						
	- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)						
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 30th September, 2014					
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	5					
	Disposed of during the quarter	5					
	Remaining unresolved at the end of the quarter	NIL					



Statement of Assets and Liabilities - Standalone

Rs. In Lacs

Particulars	As at 30th September, 2014	As at 31st March, 2014
	(Unaudited)	(Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	3,770	3,770
(b) Reserves and surplus	73,751	59,199
Sub-total - Shareholders' funds	77,522	62,970
2 Non-current liabilities		
(a) Long-term borrowings	3,092	5,222
(b) Deferred tax liabilities (net)	2,272	2,272
(c) Other long-term liabilities	1,284	1,270
(d) Long-term provisions	832	668
Sub-total - Non-current liabilities	7,479	9,432
3 Current liabilities		
(a) Short-term borrowings	14,345	2,542
(b) Trade payables	35,965	28,190
(c) Other current liabilities	6,117	6,062
(d) Short-term provisions	1,533	7,048
Sub-total - Current liabilities	57,959	43,843
TOTAL - EQUITY AND LIABILITIES	142,961	116,245
B ASSETS		
1 Non-current assets		
(a) Fixed assets	46,341	41,763
(b) Non-current investments	3,333	3,333
(c) Long-term loans and advances	4,795	4,164
Sub-total - Non-current assets	54,469	49,260
2 Current assets		
(a) Inventories	38,428	31,078
(b) Trade receivables	34,834	26,056
(c) Cash and Bank Balance	2,197	534
(d) Short-term loans and advances	13,031	9,317
Sub-total - Current assets	88,491	66,985
TOTAL - ASSETS	142,961	116,245



Notes :

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17)
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 20th October, 2014

For Alembic Pharmaceuticals Limited


Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com



F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road,
Vadodara, 390 003

RE: **LIMITED REVIEW OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER ENDED 30th SEPTEMBER, 2014 PREPARED BY THE COMPANY.**

1. INTRODUCTION

We have reviewed the accompanying statement of unaudited consolidated financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on 30th September, 2014 and the consolidated year to-date results for the period from 01-04-2014 to 30-09-2014 except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.

2. SCOPE OF REVIEW

- 2.1 We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 2.2 We report that the consolidated unaudited financial results have been prepared by the Company's management in accordance with the requirements of Accounting Standard 21 – Consolidated Financial Statements and Accounting Standard 23 Accounting for Investments in Associates in Consolidated Financial Statements issued by the Central Government under Companies (Accounting

Standards) Rules, 2006 on the basis of the separate unaudited consolidated financial results of its 100% Subsidiary i.e. Alembic Global Holding SA, Switzerland and of an Associate which have not been reviewed by us or other Auditors and are as submitted to us by the Company's management.


The unaudited consolidated financial results of Company include

- (a) Company's share (i) in the consolidated Revenue of the Subsidiary of Rs. 5098.40 Lacs for the quarter and of Rs. 8565.69 Lacs for the six months period ended on 30th September, 2014 (ii) in consolidated loss of the Subsidiary of Rs. 677.05 Lacs for the quarter and consolidated loss of Rs. 360.85 Lacs for the six months period ended on 30th September, 2014 and (iii) in the consolidated net assets of Rs.6908.17 Lacs as at the quarter and six months period ended on 30th September, 2014.
- (b) Company's share in the net profit (after tax) of the Associate of Rs. 0.79 Lacs for the quarter and of Rs. 2.57 Lacs for the six months period ended on 30th September, 2014.

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W



Rajesh S. Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 20th October, 2014

K. S. AIYAR & CO
CHARTERED ACCOUNTANTS

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road,
Vadodara 390 003.

RE: **LIMITED REVIEW OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE
QUARTER ENDED 30th SEPTEMBER, 2014 PREPARED BY THE COMPANY.**

1. INTRODUCTION


We have reviewed the accompanying statement of unaudited **standalone** financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on **30th September, 2014** except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.

2. SCOPE OF REVIEW

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act 2013 read with Rule 7




Offices also at
Chennai Kolkata Goa
Bangalore Coimbatore

K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

of the Companies (Accounts) Rules 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W



Rajesh S. Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 20th October, 2014

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for Quarter ended 30.09.2014

Revenues up by 13% at Rs 548.8 crores
PAT up by 25% at Rs 77.3 crores

Editors Synopsis

- **Net sales up by 13% to Rs 548.8 crores against Rs 487.7 crores in the corresponding quarter last year**
- **Profit before tax up by 19% to Rs 95.7 crores against Rs 80.5 crores in the corresponding quarter last year**
- **Net profit after tax up by 25% to Rs 77.3 crores against Rs 61.6 crores in the corresponding quarter last year**
- **EBITDA margins is 19.7% at Rs 108.3 crores against 19% at Rs 92.7 crores in the corresponding quarter last year**
- **India Branded formulations sales up 18% for the quarter at Rs 275.5 crores against Rs 234.1 crores in corresponding quarter last year.**
- **International Generic Formulations sales up 9% for the quarter at Rs 123.4 crores against Rs 113.7 crores in corresponding quarter last year**
- **Net sales up by 14% for H1 to Rs 1044.9 crores against Rs 916.5 crores in the corresponding H1 last year**
- **Profit before tax up by 28% for H1 to Rs 180.6 crores against Rs 141 crores in the corresponding H1 last year**
- **Net profit after tax up by 31% for H1 to Rs 141.9 crores against Rs 108.3 crores in the corresponding H1 last year**
- **EBITDA margins is 19.6% at Rs 204.9 crores for H1 against 17.9% at Rs 164.2 crores in the corresponding H1 last year**

Vadodara, 20th October, 2014

Alembic Pharmaceuticals Limited reported a 13% increase in revenues to Rs 548.8 crores for the quarter ended 30th September 2014, compared to Rs 487.7 crores in the corresponding quarter last year.

The Company posted 19% growth in profit before tax at Rs. 95.7 crores for the quarter ended 30th September 2014 against Rs 80.5 crores posted in corresponding quarter last fiscal.

The net profit grew by 25% at Rs 77.3 crores for the quarter ended 30th September 2014 against Rs 61.6 crores in corresponding quarter last fiscal.

EBITDA margins for quarter ended 30th September 2014 up at 19.7% to Rs 108.3 crores from 19% at Rs 92.7 crores for corresponding quarter last year.

The company also reported 14% increase in revenue for first half of operations to Rs 1044.9 crores against Rs 916.5 crores corresponding first half last year.

The company also posted 28% growth in profit before tax at Rs 180.6 crores for first half against Rs 141 crores for corresponding first half last year. The Company also reported 31% growth in net profit for first half at Rs 141.9 crores against Rs 108.3 crores in corresponding first half last year.

India Branded Formulations Business

The India Branded formulations business posted sales of Rs 275.5 crores against Rs 234.1 crores with a 18% growth over the corresponding quarter of the previous year.

Specialty and Acute segments grew by 18% and 17% respectively in current quarter.

International Generics

International Generic Formulation posted growth of 9% and posted sales of Rs 123.4 crores against Rs 113.7 crores over the corresponding quarter last year.

During the quarter 1 ANDA application and for the H1 4 ANDA applications were filed taking cumulative ANDA filings of the Company to 65. During the quarter 2 DMF applications were filed taking cumulative DMF filings of the Company to 68.

Summary of Total Revenue is as under:

(Rs in Lacs)

Particulars	Q2 FY15	Q2 FY14	% Change	H1 FY15	H1 FY14	% Change
Formulation						
India Branded	27551	23409	18%	49879	42606	17%
India Generics	3222	3681	(-)12%	5744	6326	(-)9%
International Branded	1836	1831	-	4104	3332	23%
International Generics	12344	11367	9%	23725	19914	19%
API	9364	7820	20%	19995	18517	8%
Export Incentives	558	659	-	1041	950	-
Total	54875	48767	13%	104488	91645	14%

The Profit break-up is as under:

(Rs in Lacs)

Particulars	Q2 FY15	Q2 FY14	% Change	H1 FY15	H1 FY14	% Change
EBITDA	10826	9271	17%	20493	16419	25%
Profit Before Tax	9569	8049	19%	18062	14099	28%
Net Profit after Tax	7727	6164	25%	14194	10828	31%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through

a marketing team of over 4400 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Alembic Pharmaceuticals Limited

Ajay Kumar Desai

Phone: +91 22 – 306 11681

Email: ajay.desai@alembic.co.in

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in